Aktieanalys

Surgical Science Q1 2024: Soft streak continues - Redeye

{newsItem.title}

Redeye Publicerad: 16 May 07:17

Surgical Science

Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educational Products sales. In contrast, Industry/OEM exceeded our estimates. Despite strong comparables, Educational Products’ weakness surprised us. We lower our estimates for the segment and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1008112/surgical-science-q1-2024-soft-streak-continues?utm_source=finwire&utm_medium=RSS

Nyheter om Surgical Science

Läses av andra just nu

Om aktien Surgical Science

Senaste nytt